QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, June 27, 2007, 27(26):7006-7010; doi:10.1523/JNEUROSCI.1919-07.2007

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Choi, S. H. Articles by Sisodia, S. S. Search for Related Content PubMed PubMed Citation Articles by Choi, S. H. Articles by Sisodia, S. S.

 Previous Article  |  Next Article 

Brief Communications
Accelerated Aß Deposition in APPswe/PS1E9 Mice with Hemizygous Deletions of TTR (Transthyretin)

Se Hoon Choi,¹ Susan N. Leight,³ Virginia M.-Y. Lee,³ Tong Li,⁴ Philip C. Wong,⁴ Jeffrey A. Johnson,⁵ Maria J. Saraiva,⁶ and Sangram S. Sisodia²

¹Committee on Neurobiology and ²Department of Neurobiology, University of Chicago, Chicago, Illinois 60637, ³Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, ⁴Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, ⁵Neuroscience Training Program, University of Wisconsin, Madison, Wisconsin 53705, and ⁶Institute of Molecular and Cellular Biology, Porto, Portugal

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
A cardinal pathological lesion of Alzheimer's disease (AD) is the deposition of amyloid ß (Aß) in the brain. We previously reported that exposing transgenic mice harboring APPswe/PS1E9 transgenes to an enriched environment resulted in reduced levels of Aß peptides and deposition, findings that were correlated with an increase in the expression of TTR, encoding transthyretin (TTR). TTR is expressed at high levels in the choroid plexus and known to bind Aß peptides and modulate their aggregation in vitro and in vivo. To explore the impact of TTR expression on Aß levels and deposition in vivo, we crossed ceAPPswe/PS1E9 transgenic mice to mice with genetic ablations of TTR. We now report that the levels of detergent-soluble and formic acid-soluble levels of Aß and deposition are elevated in the brains of ceAPPswe/PS1E9/TTR+/– mice compared with age-matched ceAPPswe/PS1E9/TTR+/+ mice. Moreover, Aß deposition is significantly accelerated in the hippocampus and cortex of ceAPPswe/PS1E9/TTR+/– mice. Our results strongly suggest that TTR plays a critical role in modulating Aß deposition in vivo.

Key words: transthyretin; presenilin 1; transgenic mice; Aß peptide; Alzheimer's disease; amyloid

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Alzheimer's disease (AD) is associated with progressive memory loss and severe cognitive decline. These clinical features are associated with deposition of 40–42 amino acid ß-amyloid (Aß) peptides in the cerebral cortex and hippocampal formation. Aß peptides are liberated from amyloid precursor proteins (APP), by the concerted action of BACE 1 (Vassar et al., 1999; Yan et al., 1999) and ""-secretase (Sisodia and St George-Hyslop, 2002; De Strooper, 2003). Early onset, familial forms of the disease (FAD) are caused by expression of mutant variants of APP, presenilin 1 (PS1), or presenilin 2 (PS2) (Price and Sisodia, 1998).

We previously reported that APPswe/PS1E9 transgenic mice exposed to an "enriched" environment exhibited reduced Aß in the cortex and hippocampus compared with APPswe/PS1E9 mice maintained in standard housing conditions (Lazarov et al., 2005). Extending these findings, our high density DNA microarray profiling studies revealed that expression of TTR, a gene encoding transthyretin (TTR), was significantly upregulated in the brains of the enriched APPswe/PS1E9 transgenic mice. TTR, a homoterameric protein of 127 amino acid subunits, is synthesized in the liver and by epithelial cells of the choroid plexus (CSF). Serum TTR is involved in the transport of thyroxine (Schreiber et al., 1990; Chanoine et al., 1992) and plasma retinol-binding protein complexed to vitamin A (Monaco, 2000). A series of biochemical and in vivo studies have revealed that TTR may also play a role in modulating Aß aggregation both in vitro and in vivo. For example, Aß forms stable complexes with TTR in vitro and prevents aggregation/amyloid formation (Schwarzman et al., 1994), whereas expression of human TTR in Caenorhabditis elegans rescues the morphological and behavioral alterations in worms expressing human Aß peptides in the muscle (Link, 1995). Finally, microarray studies of hippocampi from 6-month-old Tg2576 transgenic mice (Stein and Johnson, 2002), or cortical tissue from Tg2576/PS1^P264L/P264L mice analyzed well before the onset of Aß deposition (Wu et al., 2006), have revealed markedly elevated levels of TTR transcripts. These studies suggested that TTR gene expression was induced in response to overproduction of Aß peptides (Stein and Johnson, 2002) and that overexpressed TTR would sequester Aß species and thus preclude their subsequent aggregation and deposition.

To explore the impact of TTR expression on Aß levels and deposition in vivo, we crossed mice that harbor FAD-linked APPswe and PS1E9 transgenes (Jankowsky et al., 2001) to mice with homozygous deletions of TTR. Brain Aß levels and amyloid deposition in ceAPPswe/PS1E9/TTR+/+ or ceAPPswe/PS1E9/TTR+/– mice were examined as a function of age. We now report that amyloid deposition is accelerated and Aß levels are significantly elevated in the brains of ceAPPswe/PS1E9/TTR+/– compared with ceAPPswe/PS1E9/TTR+/+ mice at all ages examined. Our results strongly suggest that TTR plays a critical role in modulating Aß deposition in vivo.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Transgenic mice. The ceAPPswe/PS1E9 transgenic mouse line #57 (Jankowsky et al., 2001) was obtained from The Jackson Laboratory (Bar Harbor, ME). Mice with a targeted insertion into exon 2 of the TTR gene (Episkopou et al., 1993) were obtained from Dr. William Blaner (Columbia University, New York, NY).

Tissue processing. The mice were deeply anesthetized with a mixture of ketamine and xylazine and then decapitated. Isolated brains were bisected longitudinally, and hemispheres were separated and frozen on dry ice. The left hemisphere was used for examination of cerebral Aß quantification by ELISA or protein expression by Western blot analysis. The right hemisphere was kept intact for immunohistochemistry (see below).

Sandwich ELISA analysis, immunocytochemistry, and Western blot analysis. The levels of cerebral Aß were detected using ELISA protocols described previously (Suzuki et al., 1994; Turner et al., 1996). Immunostaining of sections, confocal imaging, and quantification of amyloid deposition were performed as described by Lazarov and et al. (2005). For Western blot analysis, brains were homogenized in detergent-containing buffer and subject to Western blot analysis as described previously (Lazarov et al., 2005). APP and APP-C-terminal fragments (CTFs) were detected using Ab369, raised against the APP C terminus (Xu et al., 1997). Full-length and soluble APP derivatives were detected with Ab22C11, a monoclonal antibody raised against the extracellular domain of APP (Hilbich et al., 1993), whereas the soluble derivative derived from APPswe was detected with Ab192swe (Haass et al., 1995). TTR was detected with rabbit anti-mouse TTR antibody (Sousa et al., 2007). Mouse anti--tubulin was used to normalize for protein loading.

Statistical analysis. Data are expressed as mean values ± SEM. Student's t test and ANOVA tests were applied to study the relationship between the different variables. Values of p < 0.05 were considered to be significant.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Increased levels of cerebral Aß levels in brains of hemizygous TTR-deficient mice harboring ceAPPswe/PS1E9 transgenes
The ceAPPswe/PS1E9 transgenic mouse line #57 (Jankowsky et al., 2001) harbors cointegrated APPswe and PS1E9 transgenes are driven by the mouse prion promoter (PrP). The APPswe transgene encodes a chimeric mouse-human APP695 harboring a human Aß domain and mutations (K595N, M596L) linked to Swedish FAD pedigrees (APPswe), and the human PS1E9 transgene is linked to familial AD (Borchelt et al., 1996, 1997; Lee et al., 1997). The bigenic ceAPPswe/PS1E9 were crossed with TTR-deficient mice (Episkopou et al., 1993) to generate ceAPPswe/PS1E9/TTR+/– or ceAPPswe/PS1E9/TTR+/+ mice. Although we obtained a number of ceAPPswe/PS1E9/TTR–/– in the course of breeding, we chose not to evaluate Aß levels and deposition in these animals to avoid indirect effects of TTR-deficiency that could confound our interpretations. For example, TTR-deficient mice exhibit significantly elevated expression of mRNA encoding peptidylglycine -amidating monooxygenase, the rate-limiting enzyme in neuropeptide maturation, and hence, leads to elevated levels of neuropeptide Y (NPY) (Nunes et al., 2006). NPY acts on energy homeostasis by increasing white adipose tissue lipoprotein lipase and decreasing thermogenesis. Indeed, TTR-deficient mice exhibit decreased body temperature, increased carbohydrate consumption, and preference (Nunes et al., 2006), and we observed that both TTR–/– and ceAPPswe/PS1E9/TTR–/– mice are lethargic and exhibit increased body weight relative to their hemizygous TTR (or ceAPPswe/PS1E9/TTR+/–) or TTR+/+ (or ceAPPswe/PS1E9/TTR+/+) littermates (S.H.C. and S.S.S., personal observations). In addition, the limbic forebrain of TTR-deficient mice exhibits significantly elevated levels of noradrenaline (Sousa et al., 2004), a catecholamine neurotransmitter that has been shown to modulate Aß burden in a transgenic mouse model of AD (Kalinin et al., 2007). Finally, because retinol and thyroid hormones are essential for normal mammalian brain physiology and are particularly critical during development (Porterfield and Hendrich, 1993) and because TTR is the only thyroid hormone-binding protein found at a substantial level in the CSF (Herbert et al., 1986), it is possible that TTR reduction could cause developmental abnormalities.

To examine the influence of TTR expression on cerebral steady-state levels of Aß, we generated mice that harbored ceAPPswe/PS1E9 transgenes on a TTR+/– background. Cohorts of these animals were aged for either 3, 4, 5, or 7 months. Aß levels in detergent and formic acid extracts of hemibrains of either ceAPPswe/PS1E9/TTR+/+ or ceAPPswe/PS1E9/TTR+/– mice were quantified using sandwich ELISA analysis. We show that 5-month-old ceAPPswe/PS1E9/TTR+/– mice exhibit elevated steady-state levels of detergent soluble Aß_X-40 and Aß_X-42 compared with 5-month-old ceAPPswe/PS1E9/TTR+/+ mice (Fig. 1A and B, respectively), but the differences failed to reach significance. In contrast, the levels of detergent soluble Aß_X-40 and Aß_X-42 peptides were significantly elevated in the brains of 7-month-old ceAPPswe/PS1E9/TTR+/– compared with ceAPPswe/PS1E9/TTR+/+ mice (Fig. 1A,B). These studies suggested that a fraction of Aß peptides that would otherwise aggregate and deposit remain in a detergent extractable state when TTR gene dosage is reduced. Most notably, the levels of formic acid-soluble Aß_X-40 (Fig. 1C) and Aß_X-42 (Fig. 1D) peptides were significantly elevated in the brains of the ceAPPswe/PS1E9/TTR+/– compared with ceAPPswe/PS1E9/TTR+/+ mice at both the 5 and 7 month time points, findings that would argue in support for a role of TTR in preventing Aß aggregation and subsequent deposition.

View larger version (31K): [in this window] [in a new window]   Figure 1. Genetic reduction of TTR elevates steady-state levels of cerebral Aß in the brains of ceAPPswe/PS1E9 mice. A, B, Levels of detergent-soluble AßX-40 and AßX-42 in brain extracts of ceAPPswe/PS1E9/TTR+/– and ceAPPswe/PS1E9/TTR+/+ mice at 7 month time point. C, D, Levels of formic acid-soluble AßX-40 and AßX-42 in brain extracts of ceAPPswe/PS1E9/TTR+/– and ceAPPswe/PS1E9/TTR+/+ mice at 5 and 7 month time points. The asterisk indicates a significant difference from ceAPPswe/PS1E9/TTR+/+ at p < 0.05 (3–4 animals/group). Error bars represent SE.

 
Genetic reduction of TTR leads to accelerated Aß deposition in ceAPPswe/PS1E9 mice
To examine the influence on reduced expression of TTR on amyloid deposition, brain sections from ceAPPswe/PS1E9/TTR+/– and ceAPPswe/PS1E9/TTR+/+ mice were probed with Aß-specific 3D6 antibodies (Kim et al., 2001), and bound antibodies were detected by fluorescently labeled secondary antibodies. Confocal images of amyloid burden were quantified by morphometric methods.

Although we failed to detect any significant difference in the levels of Aß deposition between genotypes at the 3 and 4 month time points, we observed a dramatic and significant elevation in amyloid deposition in the cortex of ceAPPswe/PS1E9/TTR+/– at 5 and 7 months compared with ceAPPswe/PS1E9/TTR+/+ mice (Fig. 2A, compare f and g with b and c, respectively). Similarly, amyloid deposition in the hippocampus of 7-month-old ceAPPswe/PS1E9/TTR+/– was clearly elevated compared with ceAPPswe/PS1E9/TTR+/+ mice (Fig. 2A, compare h and d, respectively). Morphometric analysis confirmed that ceAPPswe/PS1E9/TTR+/– exhibited significantly higher amyloid burden in the cortex (Fig. 2Ba) and hippocampus (Fig. 2Bb) compared with ceAPPswe/PS1E9/TTR+/+ mice at the 5- and 7-month-old time points. We then costained brain sections from 5-month-old mice with thioflavin S and 3D6 antibodies (Fig. 2C). These studies revealed that thioflavin S staining in ceAPPswe/PS1E9/TTR+/– was elevated compared with the ceAPPswe/PS1E9/TTR+/+ mice, and that this staining was at the core of the amyloid deposits in both cases.

View larger version (24K): [in this window] [in a new window]   Figure 2. Increased amyloid deposition in the cortex and hippocampus of ceAPPswe/PS1E9/TTR+/–. A, Immunohistochemical analysis of brain sections of APPswe/PS1E9/TTR+/+ (a–c, cortex, 4, 5, and 7 month; d, hippocampus, 7 month) and ceAPPswe/PS1E9/TTR+/– (e, f, cortex, 4, 5, and 7 month; h, hippocampus, 7 month) mice immunolabeled with anti-Aß 3D6 antibodies. Scale bar, 200 µm. B, Quantitative analysis of volume of amyloid burden in the cortex (a) and the hippocampus (b) of APPswe/PS1E9/TTR+/– versus APPswe/PS1E9/TTR+/+ mice. Volume is in arbitrary units (mean voxel count ± SE). The asterisk indicates a significant difference from ceAPPswe/PS1E9/TTR+/+ at *p < 0.05; **p < 0.01 (4 animals/group). Error bars represent SE. C, Thioflavine S-stained amyloid deposits in the cortex of 5-month-old ceAPPswe/PS1E9/TTR+/– versus 5-month-old ceAPPswe/PS1E9/TTR+/+ mice. Costaining of brain sections with 3D6 antibodies (a, d) and thioflavine S (b, e) and overlap (c, f). Scale bar, 50 µm.

 
Genetic reduction of TTR does not alter APP processing in ceAPPswePS1E9 mice
To assess whether alterations in APP processing might account for the observed elevations of Aß levels in ceAPPswe/PS1E9/TTR+/–, we prepared detergent-soluble extracts from these animals and ceAPPswe/PS1E9/TTR+/+ mice and subjected these preparations to Western blot analysis. To confirm the TTR genotype, extracts were probed with an anti-TTR antibody. We demonstrate that an 14 kDa TTR antibody-immunoreactive polypeptide is present in extracts from brains of ceAPPswe/PS1E9/TTR+/–, and this species is absent in extracts from ceAPPswe/PS1E9/TTR–/– mice (Fig. 3A, lanes 1 and 2, respectively). The 14 kDa immunoreactive species is also present in extracts from brains of ceAPPswe/PS1E9/TTR+/+ mice at all ages examined (Fig. 3, lanes 3, 5, 7), and the levels are clearly lower in brains of ceAPPswe/PS1E9/TTR+/– mice at all ages (Fig. 3, lanes 4, 6, 8). Analysis of Western blots using Ab369 failed to disclose any differences in the levels of full-length APP (APP-FL) or membrane-tethered APP C-terminal derivates (APP-CTFs) in extracts prepared either from ceAPPswe/PS1E9/TTR+/+ (Fig. 3B, lanes 3, 5, 7) or ceAPPswe/PS1E9/TTR+/– (Fig. 3B, lanes 1, 4, 6, 8) mice. Furthermore, we failed to observe any differences in total levels of full-length APP and soluble derivatives using Ab22C11, raised against the extracellular domain of APP, or soluble Swedish ßAPPs detected by Ab192swe between ceAPPswe/PS1E9/TTR+/+ and ceAPPswe/PS1E9/TTR+/– mice at all time points. These results suggest that genetic reduction of TTR in ceAPPswe/PS1E9 mice does not result in a discernable impact on APP processing at steady state.

View larger version (45K): [in this window] [in a new window]   Figure 3. Western blot analysis of protein extracts of brains of APPswe/PS1E9/TTR+/+ (WT), APPswe/PS1E9/TTR+/– (+/–), or APPswe/PS1E9/TTR–/– (–/–) mice. A, Western blot analysis using anti-TTR antibody. B, APP processing. Lane 1, APP-FL; Lane 2, APP-CTFs; Lane 3, -tubulin; Lane 4, full-length and soluble APP; Lane 5, soluble Swedish ßAPPs.

 

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
A series of preceding biochemical and transgenic mouse studies have provided compelling evidence that TTR plays a role in modulating Aß aggregation and deposition. For example, Aß forms stable complexes with TTR and inhibits aggregation in vitro (Schwarzman et al., 1994), and expression of human TTR rescues the morphological and behavioral alterations in C. elegans that express human Aß (Link, 1995). Indeed, studies have revealed that the levels of brain TTR were significantly lower in human AD patients compared with age-matched controls and negatively correlated with the abundance of amyloid plaques (Serot et al., 1997; Merched et al., 1998). Supporting these lines of evidence, DNA microarray studies in transgenic mice have revealed that expression of TTR mRNA is markedly elevated well before the onset of amyloid deposition (Stein and Johnson, 2002; Costa et al., 2006), suggesting that upregulation of TTR is a physiological response to elevated Aß levels that in turn blocks their aggregation. To these studies, we demonstrated that relative to APPswe/PS1E9 mice maintained in standard housing conditions, APPswe/PS1E9 transgenic mice exposed to an "enriched" environment exhibited reduced Aß deposition in the cortex and hippocampus (Lazarov et al., 2005), a setting in which steady-state levels of TTR transcripts were elevated in the brain. Collectively, these latter data provided support for the notion that TTR plays an important role in regulating Aß deposition in vivo.

In the present study, we tested the hypothesis that lowering brain levels of TTR, a protein that can sequester Aß peptides and prevent fibril formation, would accelerate amyloid deposition in APPswe/PS1E9 mice, and we now offer several important insights. First, we demonstrate that the levels of detergent-soluble Aß peptides are elevated in the brains of ceAPPswe/PS1E9/TTR+/– compared with ceAPP/PS1E9/TTR+/+ mice at all time points tested. Although these studies would suggest that lowering TTR levels might affect APP processing, we have not observed any alterations in APP metabolism in steady-state Western blot studies. Our interpretation of the finding of elevated soluble Aß levels in APPswe/PS1E9/TTR+/– mice is that these species are either oligomeric assemblies that are not deposited or represent the amorphous nonfibrillar assemblies that are present in the "penumbra" of the thioflavin-positive deposits. In any event, our confocal immunofluorescence and morphometric studies reveal that amyloid burden both in the cortex and hippocampus of ceAPPswe/PS1E9/TTR+/– was dramatically increased compared with ceAPPswe/PS1E9/+/+ mice from the 5 month time point onwards. These morphological studies were validated by sandwich ELISA analyses in which we observed that the levels of formic acid-soluble Aß_X-40 and Aß_X-42 peptides are markedly elevated in the brains of the ceAPPswe/PS1E9/TTR+/– mice at all time points. Collectively, our immunohistochemical and biochemical studies convincingly demonstrate that genetic reduction of TTR elevates Aß deposition in the brains of ceAPPswe/PS1E9/TTR+/– mice.

The nature of the interaction(s) between TTR and Aß and the mechanism(s) by which TTR alters the aggregation of Aß in vivo are not fully understood. Liu and Murphy (2006) reported that TTR significantly decreased the rate of aggregation in a strong concentration-dependent manner. Moreover, the region near tryptophan 41 of TTR is involved in binding to Aß aggregates by Trp fluorescence quenching experiments (Liu and Murphy, 2006), a finding consistent with studies showing that peptide fragments containing Trp41 of TTR bind to Aß (Schwarzman et al., 2005). Although the domain(s) within Aß that bind to TTR are not known, future efforts to obtain high-resolution information pertaining to the nature of Aß-TTR interactions would be of considerable interest.

Finally, the sites within the brain where Aß binds to TTR have not been fully resolved. Recent studies using laser dissection microscopy and PCR studies have clearly demonstrated that TTR transcripts are excluded from the brain parenchyma but restricted to choroid plexus (Sousa et al., 2007). These findings would argue that Aß_40/42, produced in the brain parenchyma, is subject to efflux into the CSF (Seubert et al., 1992; Shoji et al., 1992) where the peptides encounter TTR that is secreted from the choroid plexus and subsequently sequestered. Although this latter notion is attractive, it is important to note that TTR is not the only protein that binds Aß in CSF. Indeed, evidence has accumulated that -1-antichymotrypsin, apolipoprotein J, and apolipoprotein E, proteins present in CSF, can also bind Aß in vitro and, in certain cases, in vivo (Abraham et al., 1988; Ghiso et al., 1993; Strittmatter et al., 1993), and the respective contributions of each of these proteins to Aß clearance remains to be established. Notwithstanding the importance of these latter species to Aß metabolism in vivo, our data supporting a role for TTR in modulating Aß deposition suggest that approaches aimed at enhancing Aß sequestration and clearance with TTR as a template would be of significant therapeutic value.

	Footnotes

 
Received April 27, 2007; accepted May 18, 2007.

This work was supported by National Institutes of Health Grants AG021494 and AG027854 (S.S.S.) and by the Edward H. Levi Fund, the Adler Foundation, and Cure Alzheimer's Fund. S.S.S. discloses that he is a paid Consultant of Neuropharma, Torrey Pines Therapeutics, and Eisai Research Labs but is not a shareholder in any company that is a maker or owner of an FDA-regulated drug or device. We thank John Robinson and Yi Huang for excellent technical assistance.

Correspondence should be addressed to Sangram S. Sisodia, Department of Neurobiology, The University of Chicago, 947 East 58th Street, AB 308, Chicago, IL 60637. Email: ssisodia{at}bsd.uchicago.edu

Copyright © 2007 Society for Neuroscience 0270-6474/07/277006-05$15.00/0

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

Abraham CR, Selkoe DJ, Potter H (1988) Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52:487–501.[CrossRef][Web of Science][Medline]

Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS (1996) Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Neuron 17:1005–1013.[CrossRef][Web of Science][Medline]

Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL, Sisodia SS (1997) Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19:939–945.[CrossRef][Web of Science][Medline]

Chanoine JP, Alex S, Fang SL, Stone S, Leonard JL, Korhle J, Braverman LE (1992) Role of transthyretin in the transport of thyroxine from the blood to the choroid plexus, the cerebrospinal fluid, and the brain. Endocrinology 130:933–938.[Abstract/Free Full Text]

Costa DA, Cracchiolo JR, Bachstetter AD, Hughes TF, Bales KR, Paul SM, Mervis RF, Arendash GW, Potter H (2006) Enrichment improves cognition in AD mice by amyloid-related and unrelated mechanisms. Neurobiol Aging 28:831–844.[Web of Science][Medline]

De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38:9–12.[CrossRef][Web of Science][Medline]

Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ (1993) Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proc Natl Acad Sci USA 90:2375–2379.[Abstract/Free Full Text]

Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, Frangione B (1993) The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 293:27–30.[Web of Science][Medline]

Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, Lannfelt L, Selkoe DJ (1995) The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nat Med 1:1291–1296.[CrossRef][Web of Science][Medline]

Herbert J, Wilcox JN, Pham K-TC, Fremeau RT Jr, Zeviani M, Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman EA, Roberts JL, Schon EA (1986) Transthyretin: a choroid plexus-specific transport protein in human brain. The 1986 S. Weir Mitchell award. Neurology 36:900–911.[Abstract/Free Full Text]

Hilbich C, Monning U, Grund C, Masters CL, Beyreuther K (1993) Amyloid-like properties of peptides flanking the epitope of amyloid precursor protein-specific monoclonal antibody 22C11. J Biol Chem 268:26571–26577.[Abstract/Free Full Text]

Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157–165.[CrossRef][Web of Science][Medline]

Kalinin S, Gavrilyuk V, Polak PE, Heneka MT, Feinstein DL (2007) Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging 28:1206–1214.[CrossRef][Medline]

Kim SH, Leem JY, Lah JJ, Slunt HH, Levey AI, Thinakaran G, Sisodia SS (2001) Multiple effects of aspartate mutant presenilin 1 on the processing and trafficking of amyloid precursor protein. J Biol Chem 276:43343–43350.[Abstract/Free Full Text]

Lazarov O, Robinson J, Tang YP, Hairston IS, Korade-Mirnics Z, Lee VM, Hersh LB, Sapolsky RM, Mirnics K, Sisodia SS (2005) Environmental enrichment reduces Abeta levels and amyloid deposition in transgenic mice. Cell 120:701–713.[CrossRef][Web of Science][Medline]

Lee MK, Borchelt DR, Kim G, Thinakaran G, Slunt HH, Ratovitski T, Martin LJ, Kittur A, Gandy S, Levey AI, Jenkins N, Copeland N, Price DL, Sisodia SS (1997) Hyperaccumulation of FAD-linked presenilin 1 variants in vivo. Nat Med 3:756–760.[CrossRef][Web of Science][Medline]

Link CD (1995) Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc Natl Acad Sci USA 92:9368–9372.[Abstract/Free Full Text]

Liu L, Murphy RM (2006) Kinetics of inhibition of beta-amyloid aggregation by transthyretin. Biochemistry 45:15702–15709.[CrossRef][Medline]

Merched A, Serot JM, Visvikis S, Aguillon D, Faure G, Siest G (1998) Apolipoprotein E, transthyretin and actin in the CSF of Alzheimer's patients: relation with the senile plaques and cytoskeleton biochemistry. FEBS Lett 425:225–228.[CrossRef][Web of Science][Medline]

Monaco HL (2000) The transthyretin-retinol-binding protein complex. Biochim Biophys Acta 1482:65–72.[CrossRef][Medline]

Nunes AF, Saraiva MJ, Sousa MM (2006) Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB J 20:166–168.[Abstract/Free Full Text]

Porterfield SP, Hendrich CE (1993) The role of thyroid hormones in prenatal and neonatal neurological development–current perspectives. Endocr Rev 14:94–106.[Abstract/Free Full Text]

Price DL, Sisodia SS (1998) Mutant genes in familial Alzheimer's disease and transgenic models. Annu Rev Neurosci 21:479–505.[CrossRef][Web of Science][Medline]

Schreiber G, Aldred AR, Jaworowski A, Nilsson C, Achen MG, Segal MB (1990) Thyroxine transport from blood to brain via transthyretin synthesis in choroid plexus. Am J Physiol 258:R338–R345.[Web of Science][Medline]

Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ, Bhasin R, Silverman J, Weisgraber KH, Coyle PK, Zagorski MG, Talafous J, Eisenberg M, Saunders AM, Roses AD, Goldgaber D (1994) Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA 91:8368–8372.[Abstract/Free Full Text]

Schwarzman AL, Tsiper M, Gregori L, Goldgaber D, Frakowiak J, Mazur-Kolecka B, Taraskina A, Pchelina S, Vitek MP (2005) Selection of peptides binding to the amyloid b-protein reveals potential inhibitors of amyloid formation. Amyloid 12:199–209.[Web of Science][Medline]

Serot JM, Bene MC, Foliguet B, Faure GC (1997) Altered choroid plexus basement membrane and epithelium in late-onset Alzheimer's disease: an ultrastructural study. Ann NY Acad Sci 826:507–509.[CrossRef][Medline]

Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, Wolfert R, Selkoe D, Lieberburg I, Schenk D (1992) Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature 359:325–327.[CrossRef][Medline]

Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, Cai X-D, McKay DM, Tintner R, Frangione B, Younkin SG (1992) Production of the Alzheimer amyloid beta protein by normal proteolytic processing. Science 258:126–129.[Abstract/Free Full Text]

Sisodia SS, St George-Hyslop PH (2002) gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci 3:281–290.[CrossRef][Web of Science][Medline]

Sousa JC, Grandela C, Fernandez-Ruiz J, de Miguel R, de Sousa L, Magalhaes AI, Saraiva MJ, Sousa N, Palha JA (2004) Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem 88:1052–1058.[CrossRef][Web of Science][Medline]

Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA (2007) Transthyretin and Alzheimer's disease: where in the brain? Neurobiol Aging 28:713–718.[CrossRef][Web of Science][Medline]

Stein TD, Johnson JA (2002) Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 22:7380–7388.[Abstract/Free Full Text]

Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098–8102.[Abstract/Free Full Text]

Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264:1336–1340.[Abstract/Free Full Text]

Turner RS, Suzuki N, Chyung AS, Younkin SG, Lee VM (1996) Amyloids beta40 and beta42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem 271:8966–8970.[Abstract/Free Full Text]

Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M (1999) beta-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286:735–741.[Abstract/Free Full Text]

Wu ZL, Ciallella JR, Flood DG, O'Kane TM, Bozyczko-Coyne D, Savage MJ (2006) Comparative analysis of cortical gene expression in mouse models of Alzheimer's disease. Neurobiol Aging 27:377–386.[CrossRef][Web of Science][Medline]

Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, Brashier JR, Stratman NC, Mathews WR, Buhl AE, Carter DB, Tomasselli AG, Parodi LA, Heinrikson RL, Gurney ME (1999) Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402:533–537.[CrossRef][Medline]

This article has been cited by other articles:

				L. Liu, J. Hou, J. Du, R. S. Chumanov, Q. Xu, Y. Ge, J. A. Johnson, and R. M. Murphy Differential modification of Cys10 alters transthyretin's effect on beta-amyloid aggregation and toxicity Protein Eng. Des. Sel., August 1, 2009; 22(8): 479 - 488. [Abstract] [Full Text] [PDF]

				J. N. Buxbaum, Z. Ye, N. Reixach, L. Friske, C. Levy, P. Das, T. Golde, E. Masliah, A. R. Roberts, and T. Bartfai Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of A{beta} toxicity PNAS, February 19, 2008; 105(7): 2681 - 2686. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (11) Citing Articles via Google Scholar Google Scholar Articles by Choi, S. H. Articles by Sisodia, S. S. Search for Related Content PubMed PubMed Citation Articles by Choi, S. H. Articles by Sisodia, S. S.

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help